The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.
May 15th 2024
Study results showed systemic corticosteroids induced greater remission rates alone than in combination with other immunosuppressive treatments but were linked to adverse events.
Clinical, Pathological Distinctions Provide Basis for Differentiating IgAN, IgAVN
February 7th 2024Findings from this retrospective study help address challenges in distinguishing immunoglobulin A nephropathy from immunoglobulin A vasculitis-associated nephritis, overcoming their shared pathogenetic features.
Hydroxychloroquine, Leflunomide Improve Proteinuria, Renal Function in IgAN
February 5th 2024Hydroxychloroquine and leflunomide were found to be safe and effective for treating IgAN, with study results showing the use of both immunosuppressants in combination with a renin-angiotensin system inhibitor proved most effective in improving proteinuria and stabilizing renal function.
72-Week Phase 2B ORIGIN Data Highlight Potential Benefit of Atacicept in IgA Nephropathy
January 25th 2024The 72-week open-label extension of the phase 2b ORIGIN trial reveals atacicept's potential as a disease-modifying treatment for IgA nephropathy, showing eGFR stabilization and improvements in key indicators
Patients with IgA Nephropathy May Not Be Receiving Optimal Supportive Care
January 24th 2024Results called attention to suboptimal blood pressure and proteinuria control as well as a lack of maximal RAASI dosing in a cohort of adult patients with IgAN from the Cure Glomerulonephropathy Network study.